A renal study of the interactions between uroguanilia, urodilatia and predry bradiciiana of the chokes of the guanilato ciclase isatin and ODQ

Guanylins, natriuretic peptides (ANP and urodilatina) and bradykinin are involved in the pathophysiology, with therapeutic potential, of salt metabolism and hypertension. Objective: To study the mechanism of action and possible interactions of these peptides, with the employment of guanylate cyclase inhibitors isatina and ODQ. Method: Experiments were performed on isolated perfused rat kidney with pharmacological tools, isatin (IS; 0.3 or 10μM) or with ODQ (37μM), in studies with uroguanylin (UGN, 0.3 or 0.6μM), bradykinin (BK , 0.3 or 0.9 or 1.8nM) or urodilatin (UD, 0.03nM). It was also investigated possible interactions between those peptides. Results: Alone, IS (0.3μM), ODQ, UGN (0.3μM), BK (0.9 or 0.3nM) did not interfere significantly in perfusion perfusion (PP), in diuresis or in fractional renal tubular reabsorption of electrolytes (sodium - %TNa+; potassium - %TK+; chloride - %TCl-). In experimental conditions, ODQ proved to be effective (p<0.05) in inhibiting the effects of BK (1.8nM) on the PP (ODQ+BK120min: 111+3mmHg; BK120min: 139+5mm Hg) and %TNa+ (ODQ+BK120min: 80+1%; BK120min: 76+2%). IS (3μM) proved to be partially effective in inhibiting effects of UGN (0.6μM; IS+UGN90min: 76+2%; UGN90min: 72+2%) and BK (1.8nM; IS+BK90min: 81+2%; BK60min: 0.76+2%) on %TNa+. UD (0.03nM90min: 86+2%; UGN+UD90min: 73+4%, p<0.05) increased the natriuresis produced by UGN (0.3μM90min: 83+2%), whose vascular effects were inhibited with BK (0.3nM90min: 104+5mmHg; UGN0, 6μM; 90min: 135+4mmHg; UGN+BK90min: 110+2mmHg). Conclusions: IS and ODQ confirmed the participation of the NO-GMP signalling pathway in the mechanism of action of peptides studied. The infusion simultaneously over a peptide, proved that there are interactions in their different signalling pathway.Guanilinas, peptídeos natriuréticos (ANP e urodilatina) e bradicinina estão implicados na fisiopatologia, com potencial terapêutico, do metabolismo do sal e da hipertensão. Objetivo: Estudar o mecanismo de ação e possíveis interações destes peptídeos, pelo emprego de inibidores da guanilato ciclase isatina e ODQ. Método: Foram realizadas experiências no rim isolado e perfundido de rato com ferramentas farmacológicas, isatina (IS; 0,3 ou 10μM) ou com ODQ (37μM), nos estudos com uroguanilina (UGN; 0,3 ou 0,6μM), bradicinina (BK; 0,3 ou 0,9 ou 1,8nM) ou urodilatina (UD; 0,03nM). Investigaram-se ainda possíveis interações entre os referidos petídeos. Resultados: Isoladamente, IS (0,3μM), ODQ, UGN (0,3μM), BK (0,9 ou 0,3nM) não interferiram signficativamente na presssão de perfusão, na diurese ou na reabsorção tubular fracionada renal de eletrólitos (sódio - %TNa+; potássio - %TK+; cloreto - %TCl- ). Nas condições experimentais, ODQ mostrou-se eficaz (p<0,05) em inibir os efeitos de BK (1,8nM) sobre a pressão de perfusão (ODQ+BK120min: 111+3mmHg; BK120min: 139+5mmHg) e %TNa+ (ODQ+BK120min: 80+1%; BK120min: 76+2%). IS (3μM) mostrou-se parcialmente eficaz em inibir efeitos de UGN (0,6μM; IS+UGN90min: 76+2%; UGN90min: 72+2%) e de BK (1,8nM; IS+BK90min: 81+2%; BK60min: 0,76+2%) sobre %TNa+. UD (0,03nM90min: 86+2%; UGN+UD90min: 73+4%; p